Neonatal thrombocytopenia

Summary

Neonatal thrombocytopenia (MONDO:0024277) is a disease and 6 clinical trials. Top therapeutic interventions include platelets. A subtype of thrombocytopenia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neonatal thrombocytopenia
Mondo ID	MONDO:0024277
MeSH	D054098
SNOMED CT	82835005
UMLS	C0221028
MedGen	526130
GARD	0025379
Is cancer (heuristic)	no

Also known as: neonatal thrombocytopenia

Disease family

This is a subtype of thrombocytopenia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood platelet disease › thrombocytopenia › neonatal thrombocytopenia

Related subtypes (5): acquired thrombocytopenia, thrombocytopenia due to immune destruction, autoimmune thrombocytopenia, thrombocytopenic purpura, inherited thrombocytopenia

Subtypes (1): transient neonatal thrombocytopenia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02802982	Not specified	ACTIVE_NOT_RECRUITING	Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates
NCT03848923	Not specified	RECRUITING	Impact of Thrombocytopenia and Platelet Transfusions on Neonatal Bleeding and Inflammation
NCT04598750	Not specified	RECRUITING	The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
NCT03110887	Not specified	COMPLETED	Monitoring Outcome in Neonatal Thrombocytopenia
NCT03448952	Not specified	UNKNOWN	Neonatal Thrombocytopenia Among Newborns Admitted to Neonatal Intensive Care Unit
NCT06043050	Not specified	COMPLETED	PRedicting OutcomeS in Preterm nEonates With thromboCyTopenia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PLATELETS	3	1